Immutep Limited Corporate Presentation September 2023

Immutep Limited presents its immunotherapy pipeline focused on LAG-3 for cancer and autoimmune disease treatment. The company highlights its lead asset eftilagimod alpha (efti), demonstrating compelling clinical efficacy in combination with established cancer therapies across multiple indications including non-small cell lung cancer, breast cancer, and head and neck squamous cell carcinoma. With multiple partnerships and collaborations with large pharmaceutical companies, Immutep has a well-funded position with cash runway extending to early 2026.